所有图片(1)

文件

1.10317

Fractogel EMD BioSEC (S)

Name: Fractogel<TMSYMBOL></TMSYMBOL> EMD BioSEC (S)
Brand: MM

别名:

Fractogel^® EMD BioSEC (S)

登录查看公司和协议定价

所有图片(1)

About This Item

UNSPSC代码:

41115711

ligand

(Modified pore structure)

质量水平

400

描述

for size exclusion chromatography (SEC), suspension in 20% ethanol and 150 mM NaCl (20-40 µm)

产品线

Fractogel^®

参数

100 cm/hr max. flow rate
8 bar pressure

基质活性基团

Methacrylate

平均粒径

20-40 μm

转变温度

flash point 35 °C (calculated)

密度

1.43 g/cm³ at 20 °C

应用

viral therapy

分离技术

size exclusion (SEC)

储存温度

2-30°C

一般描述

Size exclusion chromatography for separation of proteins in the range between 5 kDa and 1000 kDa

特点和优势

Fractogel^® EMD BioSEC (S) enables users to:

Effectively remove dimer and high molecular weight aggregates and complete an efficient polishing of blood plasma factors
Determine apparent molecular weights of proteins
Move predictably and efficiently from bench scale to manufacturing scale processing
Create a robust, consistent, and transferable process

包装

Plastic bottle

分析说明

Appearance: Milky turbid suspension,free from impurities(foreign particles)
Microscopic evaluation: Uniform sphericalparticles, noagglomerates, nofines
Extractable matter (water): ≤ 0.03 %
Cerium: ≤ 1 µg/g
Pressure drop(column: ID=1.6 cm, L=10 cm at 5 ml/min): ≤ 5.0 bar
Particle size (d10): 20 - 28 µm
Particle size (d50): 24 - 34 µm
Particle size (d90): 28 - 38 µm
Colony forming units (TAMC + TYMC): ≤ 100 CFU/ml
Endotoxins: ≤ 1.00 EU/ml
Function test (b:a): ≤ 0.7
function test (c:d): ≤ 0.05
Functional Test: Separation of bovine serum albumin, ovalbumin and cytochrom C

法律信息

FRACTOGEL is a registered trademark of Merck KGaA, Darmstadt, Germany

Not finding the right product?

Try our 产品选型工具.

象形图

GHS02

警示用语：

Warning

危险声明

H226

预防措施声明

P210 - P233 - P240 - P241 - P242 - P243

危险分类

Flam. Liq. 3

储存分类代码

3 - Flammable liquids

WGK

WGK 3

闪点(°F)

95.0 °F

闪点(°C)

35 °C

分析证书(COA)

输入产品批号来搜索分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

商品

Egg-based and Cell-based Influenza Vaccine Manufacturing Methods

Influenza vaccines are commonly made using egg-based and cell-based manufacturing strategies. Find step-by-step information on the manufacturing process for each method.

Cost Modeling Vaccine Manufacturing: Estimate Production Costs for mRNA and other Vaccine Modalities

A custom-designed cost model is used to explore the economics of vaccine manufacturing across several different modalities including mRNA. The model enables greater process understanding, simulates bottlenecks, and helps to optimize production efficiency.

Developing and Manufacturing Attenuated Viral Vaccines

Learn more one the attenuated viral vaccines manufacturing process: cell culture, clarification, nuclease treatment, chromatography, and sterile filtration.

Virus-like Particle (VLP) Vaccine Bioprocessing and Formulation Steps

This technical article breaks down the steps of upstream and downstream bioprocessing and formulation of virus-like particle vaccines.

文件